National and Kapodistrian University of Athens
Ο έλεγχος του φάσματος των αντιπυρηνικών αντισωμάτων στη διαγνωστική προσέγγιση αυτοάνοσων νοσημάτων του συνδετικού ιστού: η καθιέρωση αλγορίθμου αναζήτησης των αντισωμάτων αυτών και η αξία του σε επιστημονικό και οικονομικό επίπεδο
Abstract
dc:descriptionSerological testing for the detection of autoantibodies is without doubt vital ineveryday clinical practice, regarding initial diagnosis of connective tissue disorders,their systematic monitoring as well as evaluation of treatment used.A clinical laboratory oriented towards autoimmune disorders evaluation, performs,among others, anti-nuclear (ANA) and anti-extractable nuclear antigen (anti-ENA), aswell as anti-double stranded DNA (anti-dsDNA) antibodies detection.One should consider the impact of unwarranted testing not only due to cost but alsoon timely result delivery, which can lead to prolonged undue hospitalizations andeven delays in necessitated prompt treatment so it is evident that these tests shouldbe ordered following careful consideration. To this end the presence of substantialindications of an underlying immunological disorder from the patient’s medicalhistory and current clinical presentation is essential, as well as the closecollaboration of the clinical and laboratory staff not only in interpreting results butalso in planning additional patient-tailored testing.AIMThe aim of this large retrospective study was to evaluate the presence of antinuclearantibodies as well as their specificity in autoimmune disorders diagnosis,differential diagnosis and disease prognosis. Finally, a diagnostic algorithm onsystemic autoantibodies detection and identification is proposed in order lowlaboratory cost with maximum diagnostic accuracy and value to be obtained.Patients and methodsThe study included a total of 23.822 consecutive blood samples collected over athree year period, from both hospitalized and outpatients of the “Evangelismos”General Hospital, referred to the Dept of Immunology-Histocompatibility for ANAand other specific autoantibodies testing. The majority of patients tested werefemales 70,2% (16.727) while the remaining 29,8% (7.095) males. Outpatientsamples accounted for 59,7% of the total samples assessed. During the study period different clinical Depts requested autoimmune antibody testing for hospitalizedpatients with the Internal Medicine and Neurology Depts exhibiting the largestpercentages of referrals (13,5% and 8,3% respectively).ANA were detected by indirect immunofluorescence using Hep-2 cells. Samplesreferred for anti-dsDNA antibodies were initially screened using indirectimmunofluorescence with Crithidia luciliae as a substrate and subsequently positivesamples were quantified with a radioimmunology assay (RIA). Enzyme-linkedimmunosorbent assay (ELISA) was used to screen for anti-ENA antibodies and toidentify anti-rib P, anti-HIST and anti-ENA (anti-Sm, anti-RNP, anti-SSA, anti-SSB andanti-Jo-1) antibodies. Finally, anti- Scl-70 antibodies were detected usingOuchterlony double immunodiffusion.Statistical analysisFor the results statistical analysis the program SPSS 17.0 was used. Absolute (Ν) andrelative values (%) were used for the definition of qualitative variables, whereas thePearson’s χ2 or the Fisher's exact test was applied for the correlation, where it wasnecessary. The significance level was set at 0.05.ResultsTesting for ANA was requested and performed on all samples (23.822), anti-dsDNAwere sought on a total of 18.111 samples, while anti-ENA on 13.018 samples. For themajority of samples (46,1%) the initial referral included all three of theaforementioned antibodies, while only 15,4% requested only the detection of ANA,which is however the basic screening test for immunological disorders.1. Determination of ANA fluorescence titre and pattern showed the followingresults: a. About half of the samples sent to our laboratory (11.944 - 50,1%) werenegative for ANA, while 49,9% were positive. In positive samples ANA titre ofmarginally positive values (1:160) accounted for the largest percentage (18,8%),while significantly positive titres of (>1/640) were next in frequency (13,8%). b. Speckled type fluorescence was the most commonly observed (68,40%),followed by the homogeneous type (22,4%). Pleomorphic patterns due toproliferating cell nuclear antibodies (PCNA) and Golgi apparatus were rarelyobtained, at low incidence (0,05% and 0,01% respectively).c. Highly positive samples (titres > 1:640) were more commonly found in femalesthan in males (17,2% and 5,9% respectively).2. In regards to ANA specificity, positive anti-dsDNA were noticed in 5,0% of thesamples tested. The highest percentages were found in those samples sent frompatients of the Rheumatology (19,3%) and Nephrology (15,0%) Dept and from theoutpatient pool (5,8%). Anti-dsDNA retrieval rates from other Hospital Depts weresignificantly lower (0,6%-2,5%).3. Positive anti-ENA screening tests were noticed in 11,1% of the samples tested.Outpatient samples statistically accounted for the largest percentage (11,6%).However in absolute numbers the majority of positive anti-ENA samples originatedfrom patients of the Rheumatology Dept followed by those from the InternalMedicine and Nephrology Depts.4. Statistically significant difference (p <0.001) comes out from the comparison ofANA specificity in ANA positive and ANA negative sera. Thus, in 3,4% of ANA negativescreening sera there were observed ANA specificities, like anti-Ro antibodies. Anexception is the presence of anti-rib P and anti-Jo1 in 14,8% (p=0.720) and 1,2%(p=0.702) respectively, because there is a cytoplasmic fluorescence image in Hep-2,hence negative ΑΝΑ. It is worth noticing that a statistically significant difference (p<0.001) is also recorded from the comparison of the specificity of ANA by increasingthe titre of ANA.5. Evaluation of ANA specificity and pattern of fluorescence showed that anti-dsDNAantibodies are usually associated with homogeneous patterns (23,3%), while antiENAwith speckled ones (20,1%).6. The analysis and evaluation of the repetitive ANA tests ordered (7864 samples),allows for the following observations: α. 58,2% of re-ordered testing is noticed in the out-patient pool, whilerespective percentage for Rheumatology Dept patients remain low (3,5%).b. The number of re-ordered tests per patient ranged from 2 to 15 within thethree year study period. It should also be noticed that a high percentage ofre-ordered testing (39,7%) was seen in cases of previously negative ANAresults.c. Evaluation of titre fluctuation of ANA tests revealed very low rates (1,6%,4,1% and 9%) of four, three and two fold dilution variations respectively.d. ANA re-testing was significantly higher in the first year of the study(73,2%), especially in the first trimester of the year in question (33,3%), whilethis percentage declined to 19,7% in the second year and to 7,1% in the thirdone.ConclusionsThe increasing frequency at which autoimmune disorders are observed worldwide,in association to technological evolution used over the recent years in autoantibodydetection, has led to an increase in the number of tests ordered and performed. Inthe current health care setting, which demands also reductions in costs, it is crucialto apply for a more rational use of the available autoantibody testing panel, whichtakes into account the optimal cost-benefit parameter and does not, in any way,compromise the healthcare quality offered. Taking into account the demands ofevery day clinical practice as well as several aspects of the laboratory workflow,mainly the methodology applied, we propose diagnostic guidelines which target notonly on avoiding needless testing but also in achieving the most comprehensiveapproach in evaluating autoimmune disorders.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kontou, Elisavet
- Κόντου-Χαρακοπούλου, Ελισάβετ
Subjects
dc:subject × 18- Αυτοαντισώματα
- Αντιπυρηνικά αντισώματα
- Αντισώματα έναντι δεοξυριβονουκλεϊνικού οξέος
- Αντισώματα έναντι εκχυλιζόμενων αντιγόνων πυρήνα
- Αυτοάνοσα συστηματικά νοσήματα
- Αλγόριθμος αναζήτησης αυτοαντισωμάτων
- Autoantibodies
- Antinuclear antibodies
- Anti-double stranded DNA antibody
- Anti-extractable nuclear antigens (ENA) antibodies
- Connective tissue diseases
- Diagnostic algorithm
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Επιστήμες Υγείας
- Medical and Health Sciences
- Clinical Medicine
- Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43712